THE EFFICACY COMPARISON OF MIRABEGRON AS A MONOTHERAPY VERSUS ITS COMBINATION WITH SOLIFENACIN IN OVERACTIVE BLADDER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: This review aimed to evaluate the efficacy and safety of mirabegron as monotherapy and its combination with solifenacin for patients with overactive bladder (OAB). Material & Methods: A systematic search was conducted in PubMed, Google Scholar, and Science Direct using the keywords Overactive bladder or OAB and mirabegron or beta-3 agonist or β3 adrenoreceptor agonist and solifenacin or antimuscarinic based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guideline to include relevant randomized controlled trials (RCT)s. The included studies were assessed for their risks of bias using the Cochrane risk of bias tool for randomized controlled trials. Quantitative analysis using forest plot was performed in Review Manager 5.4. Results: A total of 4 RCTs were included from 227 studies. A fixed-effects model was chosen due to the low level of heterogeneity between the studies (I2 = 0%). The average micturition volume of patients in the combination group is higher compared to the monotherapy group (MD 17.13, 95% CI 12.78 - 21.48, p < 0.00001). The mean micturition frequency (MD - 0.54, 95% CI - 0.73 - -0.34, p < 0.00001) and incontinence incidence (MD -0.30, 95% CI -0.48 - -0.12, p = 0.001) in the combined group are significantly lower compared to the monotherapy group. Conclusion: The combination of mirabegron and solifenacin has better efficacy compared to mirabegron as monotherapy for OAB patients with a therapy duration of less than 12 weeks based on the micturition volume, micturition frequency, and incontinence incidence. The administration of combination therapy would not increase adverse event incidence compared to monotherapy.
##plugins.themes.bootstrap3.article.details##
overactive bladder, beta-3 agonist, mirabegron, solifenacin
Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care. 2000; 6(11 Suppl): S565-73.
Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol. 2002; 4(Suppl 4): S7.
Nambiar AK, Bosch R, Cruz F, Lemack GE, Thiruchelvam N, Tubaro A, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2018; 73(4): 596–609.
Deeks ED. Mirabegron: A review in overactive bladder syndrome. Drugs. 2018; 78(8): 833–44.
Yoshida M, Kato D, Nishimura T, Van Schyndle J, Uno S, Kimura T. Anticholinergic burden in the Japanese elderly population: Use of antimuscarinic medications for overactive bladder patients. Int J Urol. 2018; 25(10): 855–62.
Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015; 67(3): 577–88.
Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, et al. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II). Eur Urol. 2018; 74(4): 501–9.
Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee K, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017; 120(4): 562–75.
Partin AW, Wein AJ, Kavoussi LR, Peters CA, Dmochowski RR. Campbell Walsh Wein Urology, E-Book. Elsevier Health Sciences; 2020.
Rahardjo HE. Panduan tatalaksana inkontinensia urin pada dewasa. Perkumpulan Kontinensia Indones; 2012.
Chapple CR, Kaplan SA, Mitcheson D, Blauwet MB, Huang M, Siddiqui E, et al. Mirabegron 50 mg once‐daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol. 2014; 21(10): 960–7.
Batista JE, Kölbl H, Herschorn S, Rechberger T, Cambronero J, Halaska M, et al. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol. 2015; 7(4): 167–79.
Shen YC, Wang HJ, Chuang YC. Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice. Int Urol Nephrol. 2018; 50(7): 1219–26.
Lee C-L, Ong H-L, Kuo H-C. Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder. Tzu-Chi Med J. 2020; 32(1): 30.
Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. 2006; 60(8): 959–66.
Cardozo L, Amarenco G, Pushkar D, Mikulas J, Drogendijk T, Wright M, et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double‐blind trial of solifenacin (SUNRISE). BJU Int. 2013; 111(5): 804–10.
Doroshyenko O, Fuhr U. Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009; 48(5): 281–302.
Herdman M, Nazir J, Hakimi Z, Siddiqui E, Huang M, Pavesi M, et al. Assessing preference-based outcome measures for overactive bladder: An evaluation of patient-reported outcome data from the BESIDE clinical trial. Patient-Patient-Centered Outcomes Res. 2017; 10(6): 677–86.
Krauwinkel WJJ, Kerbusch VMM, Meijer J, Tretter R, Strabach G, Van Gelderen EM. Evaluation of the pharmacokinetic interaction between the β3‐adrenoceptor agonist mirabegron and the muscarinic receptor antagonist solifenacin in healthy subjects. Clin Pharmacol Drug Dev. 2013; 2(3): 255–63.
Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol. 2016; 70(1): 136–45.
Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018; 74(3): 324–33.
Kreder KJ. Solifenacin. Urol Clin. 2006; 33(4): 483–90.
Peng L, Zeng X, Shen H, Luo D-Y. Efficacy and safety of combinations of mirabegron and solifenacin in patients with overactive bladder: a systematic review and meta-analysis. Int J Clin Exp Med. 2019; 12(2): 1355–65.